- Home
- DMLP vs EYPT Comparison
DMLP vs EYPT Comparison
Compare DMLP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMLP | EYPT |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 967.4M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DMLP | EYPT |
|---|---|---|
| Price | $22.21 | $14.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 224.2K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 14.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $143,803,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.85 | $3.91 |
| 52 Week High | $34.88 | $14.96 |
Technical Indicators
Market Signals| Indicator | DMLP | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 59.61 |
| Support Level | $21.39 | $13.61 |
| Resistance Level | $22.60 | $14.96 |
| Average True Range (ATR) | 0.75 | 0.87 |
| MACD | -0.06 | 0.12 |
| Stochastic Oscillator | 39.36 | 84.70 |
Price Performance
Historical ComparisonAbout DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.